EUVIMEDEUVIMED entdecken
Crossref

Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV

Kuan-Yin Lin, Hsin-Yun Sun, Chia-Jui Yang, Po-Liang Lu, Yuan-Ti Lee, Nan-Yao Lee, Bo-Huang Liou, Hung-Jen Tang, Mei-Hui Lee, Ning-Chi Wang, Tun-Chieh Chen, Ing-Moi Hii und 6 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Kuan-Yin Lin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, HIV Integrase Inhibitors, Isoniazid. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world experience with combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor–containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH).

Methods

From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment; secondary outcomes included treatment completion rate and safety of LTBI regimens.

Results

During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate.

Conclusions

Combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsIsoniazidLatent TuberculosisRifampinAdultFemaleHumansMaleMiddle AgedAntitubercular AgentsDrug Therapy, CombinationHeterocyclic Compounds, 4 or More RingsOxazinesPiperazinesPyridonesTreatment OutcomeAnti-Retroviral Agents

Stichwörter der Autor:innen

drug interactionintegrase strand-transfer inhibitorinterferon-gamma release assayisoniazidrifamycin

Substanzen

Antitubercular AgentsHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV Integrase InhibitorsIsoniazidOxazinesPiperazinesPyridonesRifampinAnti-Retroviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
  • College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Chien-Ching Hung

Zitieren

APA

Lin, K. Y., Sun, H. Y., Yang, C. J., Lu, P. L., Lee, Y. T., Lee, N. Y., Liou, B. H., Tang, H. J., Lee, M. H., Wang, N. C., Chen, T. C., Hii, I. M., Huang, S. H., Lin, C. Y., Tsai, C. S., Cheng, C. Y., Hung, C. C., & Taiwan HIV Study Group (2024). Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad730

Vancouver

Lin KY, Sun HY, Yang CJ, Lu PL, Lee YT, Lee NY, et al. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad730

BibTeX
@article{Lin2024,
  author = {Lin, Kuan-Yin and Sun, Hsin-Yun and Yang, Chia-Jui and Lu, Po-Liang and Lee, Yuan-Ti and Lee, Nan-Yao and Liou, Bo-Huang and Tang, Hung-Jen and Lee, Mei-Hui and Wang, Ning-Chi and Chen, Tun-Chieh and Hii, Ing-Moi and Huang, Sung-Hsi and Lin, Chi-Ying and Tsai, Chin-Shiang and Cheng, Chien-Yu and Hung, Chien-Ching and Taiwan HIV Study Group, Taiwan HIV Study Group},
  title = {Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad730}
}
Kostenlos starten →